Trump signs order seeking to upend childhood vaccine schedule

The executive order — which wasn’t accompanied by any new scientific evidence — aims to split the MMR vaccine into three separate shots and revives the administration’s attempt to slim down the immunization schedule.

By Delilah Alvarado • Aug. 11, 2026

Large pharmas skirt tariffs; BMS’ dealmaking drought

Big Pharmas won't get hit new levies on branded drugs; and aside from the megamerger rumors, BMS has had a relatively quiet year for M&A.

By PharmaVoice Staff • Aug. 7, 2026

Explore the Trendline➔

Artificial intelligence & machine learning

After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.

By PharmaVoice staff

Erica Schwartz confirmed as next CDC director

Schwartz will step into an agency that has been without a permanent leader for almost a year amid RFK Jr.’s tumultuous tenure as HHS chief. 

By Kristin Jensen • Aug. 6, 2026

What the AstraZeneca-BMS rumors reveal about pharma megamergers

Reports of talks were quickly disputed, but the prospect exposed the appeal — and antitrust risks — of combining two pharma giants.

By Kelly Bilodeau • Aug. 6, 2026

FDA allows unique endpoint in rare disease study

Global regulators are allowing the company to use hospitalization as the primary efficacy endpoint in its registration trial for a rare neuromuscular disorder.

By Alexandra Pecci • Aug. 5, 2026

Trump has another tariff plan to reshore generic drug production. Will it work?

The president’s most recent tariff proposal gives pharma more time to transition its global supply chain and reshore generic drug production.

By Kelly Bilodeau • Aug. 3, 2026

Genetic clues for cell therapy toxicities; Summit’s high-stakes FDA decision

Researchers have pinpointed genes linked to dangerous CAR-T cell therapy side effects, and a predictions market weighs in on Summit’s closely-watched cancer drug.

By PharmaVoice Staff • July 31, 2026

Kalshi is expanding online betting in drug R&D — unless detractors can stop it

Kalshi sees drug development predictions as a way to improve R&D transparency. Critics say they could create financial incentives around research and undermine public trust.

By Susanna Vogel • July 28, 2026

The FDA was all in on AI. Will that change?

High-level turnover has introduced uncertainty about how quickly the FDA’s agency-wide AI strategy will move forward.

By Kelly Bilodeau • July 24, 2026

Lilly’s leap into psychedelics; peptides in the spotlight

Eli Lilly is extending its push in neuroscience while the FDA wrestles with controversial peptide drugs. 

By PharmaVoice Staff • July 24, 2026

What’s in the FDA’s latest batch of rejection letters

A look at two recent CRLs demonstrate the tension and discrepancies between how companies and the agency communicate drug rejections.

By Alexandra Pecci • July 23, 2026

Why the FDA’s top spot could sit empty for months

Multiple factors could get in the way of confirming a new commissioner before the midterm elections, experts said, leaving the agency’s long-term initiatives in limbo.

By Susanna Vogel • July 22, 2026

What policies could last — or could get axed — amid leadership churn at FDA

How new review policies, the use of AI and other recent FDA changes are being impacted by high turnover at the top.

By Kelly Bilodeau • July 10, 2026

HHS plan to speed drug R&D won’t remove ‘self-inflicted’ delays

U.S. clinical trials continue to lose ground to China, but is Operation Trialblazer enough to help America catch up?

By Kelly Bilodeau • July 8, 2026

HHS, responding to China’s rise, moves to fast-track early drug research

A series of newly planned reforms are designed to entice companies to start early trials in the U.S. rather than overseas.

By Jonathan Gardner • June 24, 2026

As M&A rebounds, here’s how pharmas can prepare to seal a deal

Drugmakers that aren’t ready when financial opportunity knocks could get caught flat-footed in a competitive market.

By Kelly Bilodeau • June 18, 2026

Amid a flurry of biotech deals, China looks to keep innovation at home

The country's new regulatory pathway promises to accelerate access to advanced therapies for Chinese patients, but may change the licensing game for foreign companies.

By Kelly Bilodeau • June 10, 2026

BMS under pressure in schizophrenia; Summit/Akeso on a winning streak

While the large pharma’s new drug Cobenfy has stumbled in schizophrenia, it could find new life in Alzheimer’s disease

By PharmaVoice staff • June 5, 2026

House bill aims to crack down on China biotech deals

A proposal to add biotechnology to the COINS Act follows two big deals involving Pfizer and Bristol Myers, and comes amid U.S. fears that China’s drugmaking progress may threaten national security.

By Kristin Jensen • June 4, 2026

When the ISS comes down, will its drug R&D be lost in space?

 As NASA prepares to bring its hallmark space lab back to Earth, a host of private companies are emerging to fill the gap.

By Meagan Parrish • June 3, 2026

Can AI crack pharma’s drug repurposing goldmine?

With AI now capable of analyzing decades’ worth of data, FDA is pushing pharma to leverage its “enormous, untapped value” by repurposing drugs.

By Alivia Kaylor • May 29, 2026

Can a chaotic FDA still deliver on faster drug development?

As leadership changes create more instability at the agency, here's what it'll take to keep speedier drug approvals on track. 

By Kelly Bilodeau • May 26, 2026

China’s biotech rise sparks new US industry alliance

The nonprofit is aiming to inspire a new moonshot effort that helps the U.S. maintain its position as a drug innovation leader.

By Kelly Bilodeau • May 21, 2026

Sanofi’s vaccine bump; the new FDA commish

A look at how vaccine makers are scraping by, and at the incoming acting FDA head, Kyle Diamantas.

By PharmaVoice staff • May 15, 2026

Former Ovid CEO Dr. Jeremy Levin’s rallying cry for biotech

The long-time pharma exec is on a quest with a new book and bold message for biotech leaders and U.S. lawmakers.

By Meagan Parrish • May 15, 2026